- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02623309
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Allogeneic (Allo) hematopoietic stem cell transplantation (HSCT) is a recognized curative procedure for hematological malignancies. It is now well known that this property is related to the graft-versus-tumor (GVT) effect developed from the immunocompetent cells contained in or generating from the donor graft. For years, however, and despite this unique antitumoral activity, Allo-HSCT has been restricted to a limited number of patients due to two major limitations: the toxicity of the procedure and the absence of a donor for every single patients. More recently the stage has dramatically changed with respect to these two restraints. Over the last decade, many studies have established the feasibility of Allo-HSCT in older patients but the availability of MRD is even less frequent in elderlies, likely related to medical contraindication for graft donation or sibling deaths. UD are routinely used but associated with a high incidence of GVHD. As compared to younger populations, unrelated cord-blood HSCT is seldom performed in this population and numbers decrease with age due to the feared risk of supposed increased lethal infectious complications related to the effect of the delayed immune reconstitution in elderlies. Thus the need for alternative donors allowing for a safe and efficient transplantation is still unmet. In consequence, overall, despite the fact that Allo-HSCT feasibility has been established in the oldest patients, all these lacks contribute eventually to maintain a low rate of allo-HSCT performed in a population with the higher incidence of hematologic malignancies that usually present with the poorest prognosis.
Thus it is critical developing innovative efficient therapeutic strategies answering this unmet-medical need. In this perspective, Haplo-HSCT could represent a part of the answer in this aged population. It offers the potential advantage to offer a rapid donor determination for virtually every single patient. In addition, our data suggest that in elderlies haplo-HSCT using T-repleted graft, RIC and PT-HDCy presents low NRM and retains an antitumor effect despite low GVHD incidences. They also suggest that haplo-HSCT may conduct to better outcome than URD-HSCT as an alternative to MRD-HSCT. It may also be associated with lower costs (no graft purchase and low post-transplant complications rate) and better QOL likely related to low cGVHD-rate. In addition the conduct of such trial at a time when the diffusion of the strategy in this population is just starting is really crucial before widespread uncontrolled dissemination.
The investigators propose to address this question by prospectively comparing these 2 strategies in elderly patients without MRD, in terms of efficacy, safety and including the prospective evaluation study of quality-of-life (QOL). They will conduct a national, multicenter, open-label, comparative, randomized phase III trial in patients with hematological malignancies justifying an allo-HSCT from an alternative donor when a MRD has not been identified.
When MRD search is recognized to be a failure, patients will be included in the clinical trial after informed consent and randomized in the two strategies based on donor search:
- Reference group: Unrelated Donor group
- Investigational group: Haplo Donor Group
Investigators will use a composite end-point embracing the three main causes of failure: death, relapse and severe cGVHD (as a surrogate endpoint for QOL). We will analyze the HSCT usual objectives as GHVD, NRM, relapse and survival. A specific study of patients' health related quality of life will also be conducted using the FACT-BMT questionnaire. In addition, the success of the two strategies in term of transplant completion (donor determination, transplant realization and time to do so) will be compared.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Amiens, France
- CHU Amiens
-
Besançon, France
- CHU Besançon
-
Clermont-ferrand, France
- CHU Estaing/Clermont-ferrand
-
Grenoble, France
- CHU Albert Michallon
-
Limoges, France
- CHU Limoges
-
Marseille, France, 13009
- Institut Paoli Calmettes
-
Montpellier, France
- CHRU Montpellier
-
Nantes, France
- CHU Nantes
-
Paris, France
- Hopital Saint Antoine
-
Paris, France
- Hôpital Saint louis
-
Paris, France
- Hopital Necker
-
Pessac, France
- Hôpital Haut Lévêque
-
Saint Priest en Jarez, France
- Institut de Cancérologie Lucien Neuwirth
-
Toulouse, France
- IUCT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged of 55 years or up to 70 years.
- Patients with hematological malignancy
- Patients without a matched related donor
- Patients eligible for an allogeneic HSCT from an alternative donor
- Able to comply with the protocol
- Written informed consent
- Affiliation to Social Security System
Exclusion Criteria:
- Clinical or biological contraindication to allogeneic HSCT
- Other evolutive cancer
- Positive serology for HIV, hepatitis B or chronic active hepatitis C
- Pregnant or breast-feeding women.
- Emergency
- Patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAPLO graft
Conditioning regimen
Prophylaxis regimen for GVHD
Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg GCSF (Neupogen ®) during 4 to 5 days (D-4 to D-1): SC 10 µg/kg/d. |
|
Active Comparator: MUD graft
Conditioning regimen
Prophylaxis regimen for GVHD
Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Event-free survival with death, relapse or occurrence of severe cGVHD as event whatever occurs first
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Engraftment: time to reach 0.5 x 109/l ANC, 20 x 109/l platelets and full donor lymphoid chimerism
Time Frame: 5 years
|
5 years
|
Acute and chronic GVHD cumulative incidences
Time Frame: 5 years
|
5 years
|
Non-relapse mortality cumulative incidence
Time Frame: 5 years
|
5 years
|
Relapse incidence
Time Frame: 5 years
|
5 years
|
Probabilities of overall survival and progression-free survival
Time Frame: 5 years
|
5 years
|
Evaluation of HRQL including patients who relapse
Time Frame: 5 years
|
5 years
|
Evaluation of procedure costs from beginning of search until death or two-year follow-up
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Didier Blaise, MD, Institut Paoli-Calmettes
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HAPLOMUDELDERLY-IPC 2015-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Neoplasms
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Massachusetts General HospitalRecruiting
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedHematologic MalignancyUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark
-
SecuraBioCompletedHematologic MalignancyUnited States, Italy
-
Duke UniversityActive, not recruitingHematologic MalignancyUnited States
-
St. Petersburg State Pavlov Medical UniversityCompleted
Clinical Trials on Allogeneic (Allo) hematopoietic stem cell transplantation
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedAcute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Minimal Residual Disease | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic... and other conditionsUnited States
-
Wake Forest University Health SciencesCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Karolinska InstitutetKarolinska University HospitalTerminatedPancreatic AdenocarcinomaSweden
-
Hadassah Medical OrganizationUnknown
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Northwestern UniversityTerminated
-
Hospital Universitario La PazUniversity of MalagaRecruitingTransplant-Related DisorderSpain
-
Institute of Hematology & Blood Diseases HospitalRecruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...WithdrawnAnemia | Thrombocytopenia | Neutropenia | Hematopoietic/Lymphoid Cancer | Lymphopenia
-
Asan Medical CenterPusan National University HospitalCompletedMyelodysplastic Syndromes | LeukemiaKorea, Republic of